Richard B. Moss

Publications

• Sleep-disordered breathing in children with spinal muscular atrophy Type II and III Yuan N, Moss R, Wang C. submitted.
• Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis J, Guleria R, Moss R, Denning D. Clin Exp Allergy. 2013: in press
• Current Treatment Options for Invasive Aspergillosis Batista MV, Costa SF, Shikanai-Yasuda MA, Moss RB. Drugs of Today. 2013; 49 (3): 213-226
• Current trials in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization Moss RB, Eur Infect Dis. 2013; (in press)
• Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. Moss RB, J Pediatr. 2013; 162 (4): 676-80
• Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL. J Cyst Fibros. 2013; 12 (3): 241-8
• Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. Ruddy J, Emerson J, Moss R, Genatossio A, McNamara S, Burns JL, Anderson G, Rosenfeld M. J Aerosol Med Pulm Drug Deliv. 2013; 26 (2): 69-75
• Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens. Gernez Y, Dunn CE, Everson C, Mitsunaga E, Gudiputi L, Krasinska K, Davies ZA, Herzenberg LA, Tirouvanziam R, Moss RB. J Cyst Fibros. 2012; 11 (6): 502-10
• Fungi and allergic lower respiratory tract diseases Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, Greenberger PA, Kariuki B, Kita H, Kurup VP, Moss RB, Niven RM, Pashley CH, Slavin RG, Vijay HM, Wardlaw AJ. J Allergy Clin Immunol. 2012: 129 280-291
• Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB. J Cyst Fibros. 2012; 11 (6): 539-49
• Results of a Phase 2a study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis and homozygous for the F508del-CFTR mutation Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Campbell PW, Bronsveld I, DeBoeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Lebecque P, McCoy KS, Moss RB, Pilewski JM, Rosenbluth D, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Thorax. 2012; 67 (1): 12-18
• The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. Moss RB, Ann N Y Acad Sci. 2012: 1272 49-57
• A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS. N Engl J Med. 2011; 365 (18): 1663-72
• Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW. Arch Pediatr Adolesc Med. 2011; 165 (9): 847-56
• Denufosol Tetrasodium by Inhalation in Patients with Cystic Fibrosis and Mild Pulmonary Function Impairment Accurso FJ, Moss RB, Wilmott RW, Anbar RD, Schaberg AE, Durham TA, Ramsey BW, TIGER-1 Investigator Study Group. Am J Resp Crit Care Med. 2011: 183 627-634
• Lessons learned from the denufosol trials Moss RB, Pediatric Pulmonology. 2011: Suppl 34 177-178
• Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ. J Pediatr. 2011; 159 (5): 819-824.e1
• Allergic bronchopulmonary aspergillosis Moss RB, eCysticFibrosis Review (http://www.hopkinscme.net/ofp/eCysticFibrosisReview/index.html). 2010
• Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Moss RB, Curr Opin Pulm Med. 2010; 16 (6): 598-603
• Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL. Pediatr Pulmonol. 2010; 45 (9): 934-44
• Cystic Fibrosis Pathophysiology and Therapeutic Targets. Moss RB, Johns Hopkins Advanced Studies in Medicine.. 2010: 10 9-13
• Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW. N Engl J Med. 2010; 363 (21): 1991-2003
• Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial. Yuan N, Kane P, Shelton K, Matel J, Becker BC, Moss RB. J Child Neurol. 2010; 25 (7): 815-21
• Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, Dunn CE, Davies ZA, Moss RB, Herzenberg LA, Herzenberg LA, Tirouvanziam R. Proc Natl Acad Sci U S A. 2009: 106 5779-5783
• Allergic bronchopulmonary aspergillosis Moss RB, In Latge JP, Steinbach WJ, Eds. Aspergillus Fumigatus and Aspergillosis. American Society of Microbiology Press. 2009: 332-350
• Cystic fibrosis HRCT scores correlate strongly with Pseudomonas infection. Robinson TE, Leung AN, Chen X, Moss RB, Emond MJ. Pediatr Pulmonol. 2009; 44 (11): 1107-17
• Genetic modifiers of liver disease in cystic fibrosis. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR. JAMA. 2009; 302 (10): 1076-83
• Highlights of a workshop to discuss targeting inflammation in cystic fibrosis Banner K, De Jonge H, Elborn S, Growcott E, Gulbins E, Konstan M, Moss R, Poll C, Randell SH, Rossi AG, Thomas. J Cystic Fibrosis. 2009; 8 (1): 1-9
• Infection, inflammation and the downward spiral of cystic fibrosis lung disease Moss RB, Journal of Pediatrics. 2009: 154 162-163
• Chest imaging in cystic fibrosis Robinson TE, Moss RB. Commentaries on Chronic Airway Infection. 2008; 2 (3): 2-8
• Management of allergic aspergillosis Moss RB, Current Fungal Infection Reports. 2008: 2 87-93
• Profound functional and signalling changes in viable neutrophils homing to cystic fibrosis airways Tirouvanziam R, Gernez Y, Conrad CK, Moss RB, Schrijver I, Dunn CE, Davies ZA, Herzenberg LA, Herzenberg LA. Proceed Natl Acad Sci USA. 2008: 105 4335-4339
• The role of fungi in chronic airways infection Moss RB, Commentaries on Chronic Airway Infection. 2008; 2 (14): 2-8
• Aggressive treatment strategies in the fight against cystic fibrosis Mogayzel PJ, Clancy JP, Moss RB, Johns Hopkins Advanced Studies in Medicine. 2007; 7 (14): 426-458
• Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Gibson RL, Emerson J, Hamblett N, Burns JL, McNamara S, Accurso F, Konstan MW, Chatfield BA, Retsch-Bogart G, W. Pediatric Pulmonology. 2007: 42 610-623
• No detectable improvements in CFTR by nasal aminoglycosides in CF patients heterozygous for stop mutations. Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson RL, Zeitlin P, Berclaz Y, Moss R, Knowles M, Oster RA, Mayer-Ham. Am J Resp Molec Cell Biol. 2007: 37 57-66
• Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo controlled trial. Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J. Human Gen Ther. 2007: 18 726-732
• Gene therapy for cystic fibrosis: the rise and fall of a viral vector Moss RB, US Respiratory Disease. 2006: 40
• High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. Proc Natl Acad Sci U S A. 2006; 103 (12): 4628-33
• Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan MW, Wagener J, Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann CM, Aitken ML, Mahl TC, Young KR, Dunitz J, Murray FT. Pancreas. 2006; 32 (3): 258-63
• Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA. Kurup VP, Knutsen AP, Moss RB, Bansal N. Clin Molec Allergy. 2006; 4 (1): 11 [EPub]
• The urokinase type plasminogen activator system in induced sputum of patients with asthma Wang L, Xiao W, Moss RB, Hsu YP. Chinese J TB Resp Dis. 2006: 29 124-7
• Aspergillus antigens and immunodiagnosis of allergic bronchopulmonary aspergillosis. Kurup VP, Knutsen AP, Moss RB.. In Kurup VS, Ed. Mold Allergy, Biology and Pathogenesis. Research Signpost.. 2005; 37/661 (2): 137-146
• Diagnostic testing by comprehensive mutation analysis in a large group of Hispanics: novel mutations and assessment of a population-specific mutation spectrum Schrijver I, Ramalingam S, Sankaran R, Swanson S, Dunlop CLM, Keiles S, Wassman EF, Moss R, Oehlert J, Gardner P, Kammesheidt.. J Molec Diagnostics. 2005; 7 (2): 289-99
• Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, Moss RB. Chest. 2005; 128 (4): 2327-35
• Fully automated system for three-dimensional bronchial morphology analysis using volumetric multidetector computed tomography of the chest Venkatraman R, Raman R, Raman B, Moss RB, Rubin GD, Mathers LH, Robinson TE. J Digital Imaging. 2005: Dec 13 Epub
• Fungal allergy in cystic fibrosis Moss RB, Kurup VS, Ed. Mold Allergy, Biology and Pathogenesis. Research Signpost.. 2005; 37/661 (2): 93-104
• Novel contributions to the Asian CFTR mutation spectrum: genotype and phenotype in Thai patients with cystic fibrosis. Schrijver I, Karnsakul W, Ramalingam S, Sankaran R, Moss R, Gardner P. Am J Med Genet. 2005: 133 103-5.
• Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. Moss RB, Med Mycol. 2005: 43 Suppl 1 S203-6
• Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Moss RB., Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K.. Pediatr Pulmonol. 2005; 39 (3): 209-18
• Sputum cathelicidin, plasmin activation system components and cytokine patterns discriminate cystic fibrosis, chronic obstructive pulmonary disease and asthma from each other and healthy subjects Xiao W, Hsu YP, Ishizaka A, Kirikae, Moss RB. Chest. 2005: 28 2316-2326
• Allergic bronchopulmonary aspergillosis with normal serum IgE in a child with cystic fibrosis Dorsaneo D, Borowitz D, Sharp J, Moss R. Ped Asthma Allergy Immunol. 2004: 17 146-150
• Inhalational antibiotics for airways infection Moss RB, Experimental Lung Research. 2004; 30 (Suppl 1): 58-61
• Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. Moss RB, Clin Exp Immunol. 2004; 135 (3): 358-60
• Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. Bonnel AS, Song SM, Kesavarju K, Newaskar M, Paxton CJ, Bloch DA, Moss RB, Robinson TE. Pediatr Pulmonol. 2004; 38 (5): 396-405
• Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE. Chest. 2004; 125 (2): 509-21
• Cystic Fibrosis: Treatment Practice Guidelines Pocket Guide. Professional Resources in Management Education, Inc Bloch EA, Germana J, Konstan M, Kuhn R, Llewellyn A, Moss R, Nickerson B, Rinker K, Sufian BS, VanDevanter D, Wagener J. Cystic Fibrosis: Treatment Practice Guidelines Pocket Guide. Professional Resources in Management Education, Inc. 2004
• AAV-CFTR gene therapy for cystic fibrosis: retrospect and prospect Carter BJ, Munson K, Burstein H, Peluso R, Gerard C, Guggino W, Engelhardt J, Flotte T, Moss R. Pediatr Pulmonol. 2003: Suppl 25 159-60
• AAV-CFTR gene therapy for cystic fibrosis: retrospect and prospect. Carter BJ, Munson K, Burstein H, Peluso R, Gerard C, Guggino W, Engelhardt J, Flotte T,Moss R.. Pediatric Pulmonology. 2003: Suppl 25 159-160
• Advances against aspergillosis. Steinbach WJ, Stevens DA, Denning DW, Moss RB. Clin Infect Dis. 2003: 37 Suppl 3 S155-6
• Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G. Clin Infect Dis. 2003: 37 Suppl 3 S225-64
• Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Chan FP, Bloch DA, Holmes TH, Moss RB. Am J Respir Crit Care Med. 2003; 168 (5): 588-93
• Cystic Fibrosis Foundation Consensus Conference recommendations on diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis: executive summary Moss RB, Stevens DA. CFF Consensus Conferences. 2003 X Sect 3
• Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B. Am J Respir Crit Care Med. 2003; 167 (6): 841-9
• A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, Brown BW, Desch JK, Norbash AM, Conrad CK, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Reynolds TC, Moss RB, Gardner P. Hum Gene Ther. 2002; 13 (11): 1349-59
• Allergic bronchopulmonary aspergillosis. Moss RB, Clin Rev Allergy Immunol. 2002; 23 (1): 87-104
• Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Moss RB, Chest. 2002; 121 (1): 55-63
• A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. Hum Gene Ther. 2001; 12 (15): 1907-16
• Administration of aerosolized antibiotics in cystic fibrosis patients. Moss RB, Chest. 2001; 120 (3 Suppl): 107S-113S
• Comprehensive mutation screening in a cystic fibrosis center. Wine JJ, Kuo E, Hurlock G, Moss RB. Pediatrics. 2001; 107 (2): 280-6
• Cystic fibrosis: new insights and treatments Moss RB, Hospital Practice, online at http://www.hosppract.com/issues/2001/01/moss.htm. 2001: 25-37
• Cystic fibrosis: new insights and treatments Moss RB, Hospital Practice. 2001: 36 25-37
• New approaches to cystic fibrosis. Moss RB, Hosp Pract (1995). 2001; 36 (1): 25-7, 31-2, 35-7
• Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Hubli S, Moss RB. J Pediatr. 2001; 138 (4): 553-9
• Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Moss RB, Hsu YP, Olds L. Clin Exp Immunol. 2000; 120 (3): 518-25
• Novel Cystic Fibrosis mutation L1093P: functional analysis and possible Native American origin. Yee K, Robinson C, Hurlock G, Moss RB, Wine JJ. Hum Mutat. 2000; 15 (2): 208
• Pulmonary sequelae of bronchopulmonary dysplasia survivors: high-resolution CT findings. Howling SJ, Northway WH, Hansell DM, Moss RB, Ward S, Müller NL. AJR Am J Roentgenol. 2000; 174 (5): 1323-6
• Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. Wagner JA, Nepomuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, Moss RB, Wine JJ, Gardner P. J Gene Med. 1999 Jan-Feb; 1 (1): 13-21
• Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Nepomuceno IB, Esrig S, Moss RB. Chest. 1999; 115 (2): 364-70
• Anti-arthropod saliva antibodies among residents of a community at high risk for Lyme disease in California. Lane RS, Moss RB, Hsu YP, Wei T, Mesirow ML, Kuo MM. Am J Trop Med Hyg. 1999; 61 (5): 850-9
• BioMedNet Interview 1 Oct 1999 Moss RB, HMS Beagle (on-line, site closed 30 June 2004). 1999
• Chronic intermittment administration of inhaled tobramycin in patients with cystic fibrosis Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev M, et al for the Cystic Fibrosis Inhaled Tobramycin Study Group (member).. N Engl J Med. 1999: 340 23-30
• Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Redding G, Rubio T, Williams-Warren J, Wilmott R, Wilson HD, Yogev R. J Pediatr. 1999; 134 (4): 413-21
• Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H. Am J Physiol. 1999; 277 (4 Pt 1): C833-9
• Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials Wagner JA, Nepumuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, Moss RB, Wine JJ, Gardner P. J Gene Med. 1999: 109 13-21
• Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus Wagner JA, Moran ML, Messner AH, Diafuku R, Kouyama D, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner. Laryngoscope. 1999: 109 266-74
• Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. Laryngoscope. 1999; 109 (2 Pt 1): 266-74
• Standardized high-resolution CT of the lung using a spirometer-triggered electron beam CT scanner. Robinson TE, Leung AN, Moss RB, Blankenberg FG, al-Dabbagh H, Northway WH. AJR Am J Roentgenol. 1999; 172 (6): 1636-8
• Two novel mutations in a cystic fibrosis patient of Chinese origin. Wagner JA, Vassilakis A, Yee K, Li M, Hurlock G, Krouse ME, Moss RB, Wine JJ. Hum Genet. 1999; 104 (6): 511-5
• A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Mickle JE, Macek M, Fulmer-Smentek SB, Egan MM, Schwiebert E, Guggino W, Moss R, Cutting GR. Hum Mol Genet. 1998; 7 (4): 729-35
• A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Wagner JA, Moran ML, Messner AH, Daifuku R, Conrad CK, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. Hum Gene Ther. 1998; 9 (6): 889-909
• Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. Bhudhikanok GS, Wang MC, Marcus R, Harkins A, Moss RB, Bachrach LK. J Pediatr. 1998; 133 (1): 18-27
• Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR, Gardner P. Lancet. 1998; 351 (9117): 1702-3
• A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems Eisenberg J, Aerosolized Tobramycin Study Group (member).. Chest. 1997: 1112 955-62
• Activation of eosinophils in the airways of lung transplantation patients. Dosanjh AK, Elashoff D, Kawalek A, Moss RB, Esrig S. Chest. 1997; 112 (5): 1180-3
• Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations Wilmott RW, Amin RS, Colin A, Devault A, Dozor AJ, Eigen H, Johnson C, Lester LA, McCoy K, McKean LP, Moss R, Nash ML, Pagel Jue C, Regelmann W, Stokes DC, Fuchs HJ. Am J Respir Crit Care Med. 1996: 153 1914-7
• Correlates of osteopenia in patients with cystic fibrosis. Bhudhikanok GS, Lim J, Marcus R, Harkins A, Moss RB, Bachrach LK. Pediatrics. 1996; 97 (1): 103-11
• Immune therapies for lung infection in cystic fibrosis Moss RB, IACFA Newsletter. 1996: 46 8-13
• Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, Gardner P. Clin Exp Immunol. 1996; 106 (2): 374-88
• When to use a HEPA filter for atopic childhood asthma Moss RB, J Respir Dis. 1996: 17 806
• Activation of CFTR chloride current by nitric oxide in human T lymphocytes. Dong YJ, Chao AC, Kouyama K, Hsu YP, Bocian RC, Moss RB, Gardner P. EMBO J. 1995; 14 (12): 2700-7
• Alternative pharmacotherapies for steroid-dependent asthma. Moss RB, Chest. 1995; 107 (3): 817-25
• Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Moss RB, Clin Infect Dis. 1995; 21 (4): 839-49; quiz 850-1
• Inflammatory response in cystic fibrosis lung disease Moss RB, New Insights into Cystic Fibrosis. 1995: 324 1-6
• Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery. Moss RB, King VV. Arch Otolaryngol Head Neck Surg. 1995; 121 (5): 566-72
• New drugs for cystic fibrosis lung disease. Moss RB, West J Med. 1995; 162 (4): 354-5
• Practice parameters for the diagnosis and treatment of asthma Spector SL, Nicklas RA, Joint Task Force on Practice Parameters (member).. J Allergy Clin Immunol. 1995: 96 707-870
• Sinus disease in cystic fibrosis Light M, Moss RB, Davidson TM. Gershwin EM and Incaudo GA, Eds. Diseases of the Sinuses: A Comprehensive Textbook of Diagnosis and Treatment. Humana Press, Inc., Totowa NJ. 1995: 357-65
• Aerosolized recombinant human DNase reduces respiratory exacerbations and improves pulmonary function in patients with cystic fibrosis Fuchs HJ, Borowitz DS, Christiansen DH, et al for the Pulmozyme® Study Group (member).. N Engl J Med. 1994: 331 637-42
• Differential diagnosis of asthma in children Moss RB, Gershwin ME and Halpern GM, Eds. Bronchial Asthma. Principles of Diagnosis and Treatment, 3rd Ed, The Humana Press Inc., Totowa NJ. 1994: 141-69
• Osteopenia in adults with cystic fibrosis. Bachrach LK, Loutit CW, Moss RB. Am J Med. 1994; 96 (1): 27-34
• Outcome measures for clinical trials in cystic fibrosis Ramsey BW, Boat T, Accurso F, Bennett W, Boucher R, Brody A, Crystal R, Cutting G, Davis P, Dorkin H, Fleming T. Kaplan R, Knowles M, Konstan M, Laube B, McElvaney G, Morgan W, Moss R, Orenstein R, Pencharz P, Rosenstein B, Schidlow D, Smith A, Spino M, Stallings V, Stecenko A, Terrin M, Weatherly M, Wilmott R, Wilson C, Wood. J Pediatr. 1994: 124 177-92
• Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: II. A histopathologic analysis. Cheung AT, Moss RB, Kurland G, Leong AB, Novick WJ. J Med Primatol. 1993; 22 (4): 257-62
• Immunopathogenesis of cystic fibrosis lung disease Moss RB, Hillman B (ed). Pediatric Respiratory Diseases: Diagnosis and Treatment. W.B. Saunders, Philadelphia. 1993: 674-87
• Pulmonary defenses Moss RB, Hillman B (ed). Pediatric Respiratory Diseases: Diagnosis and Treatment. W.B. Saunders, Philadelphia, Hillman B (ed). Pediatric Respiratory Diseases: Diagnosis and Treatment. W.B. Saunders, Philadelphia. 1993: 36-46
• Sinusitis and polyposis in cystic fibrosis Moss RB, Druce HM, Ed. Sinusitis--Pathophysiology and Treatment. Marcel Dekker, New York. 1993: 247-81
• [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis]. Moss RB, Infusionsther Transfusionsmed. 1993: 20 Suppl 1 42-6; discussion 47
• Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: I. Effects of pentoxifylline on neutrophil influx. Cheung AT, Moss RB, Leong AB, Novick WJ. J Med Primatol. 1992 Sep-Oct; 21 (7-8): 357-62
• Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infection. Moss RB, Carmack MA, Esrig S. J Pediatr. 1992; 120 (1): 16-21
• Gastroesophageal reflux-associated lung disease Moss RB, Prober CG, Behrman RE (eds). Nelson Self-Assessment in Pediatrics, CME Supplement Test No. ZN9212. 1992
• Selective polysaccharide antibody deficiency in familial DiGeorge syndrome. Schubert MS, Moss RB. Ann Allergy. 1992; 69 (3): 231-8
• The role of sinus surgery in chronic sinusitis in children King VV, Moss RB. Am J Allergy Asthma Pediatr. 1992: 5 203-8
• Drug allergy in cystic fibrosis. Moss RB, Clin Rev Allergy. 1991 Spring-Summer; 9 (1-2): 211-29
• Evaluation of the immunologic cross-reactivity of aztreonam in patients with cystic fibrosis who are allergic to penicillin and/or cephalosporin antibiotics. Moss RB, McClelland E, Williams RR, Hilman BC, Rubio T, Adkinson NF. Rev Infect Dis. 1991 May-Jun: 13 Suppl 7 S598-607
• Anaphylaxis from a tick bite Van Wye JE, Hsu YP, Lane RS, Terr AI, Moss RB. N Engl J Med. 1991: 324 777-8
• Anaphylaxis from a tick bite. Van Wye JE, Hsu YP, Terr AI, Moss RB, Lane RS. N Engl J Med. 1991; 324 (11): 777-8
• IgE antibodies in tick bite-induced anaphylaxis. Van Wye JE, Hsu YP, Lane RS, Terr AI, Moss RB. J Allergy Clin Immunol. 1991; 88 (6): 968-70
• Immunoglobulin G subclasses. Moss RB, West J Med. 1991; 154 (4): 458
• Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. Moss RB, J Allergy Clin Immunol. 1991; 87 (1 Pt 1): 78-88
• Antibody production in cystic fibrosis and possibilities for immunotherapy Moss RB, Pediatr Pulmonol. 1990: Suppl 5 66-7
• Drug allergy in cystic fibrosis Moss RB, Moss RB (ed). Cystic Fibrosis. Infection, Immunopathology, and Host Response. Humana Press, Clifton NJ. 1990: 211-29
• Late pulmonary sequelae of bronchopulmonary dysplasia. Northway WH, Moss RB, Carlisle KB, Parker BR, Popp RL, Pitlick PT, Eichler I, Lamm RL, Brown BW. N Engl J Med. 1990; 323 (26): 1793-9
• Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Van Wye JE, Collins MS, Baylor M, Pennington JE, Hsu YP, Sampanvejsopa V, Moss RB. Pediatr Pulmonol. 1990; 9 (1): 7-18
• Sinus disease in patients with severe cystic fibrosis: relation to pulmonary exacerbation. Umetsu DT, Moss RB, King VV, Lewiston NJ. Lancet. 1990; 335 (8697): 1077-8
• Cystic Fibrosis. Infection, Immunopathology, and Host Response. Humana Press, Clifton NJ Moss RB, Cystic Fibrosis. Infection, Immunopathology, and Host Response. Humana Press, Clifton NJ. 1990: 1-251
• Allergic etiology and immunology of asthma. Moss RB, Ann Allergy. 1989; 63 (6 Pt 2): 566-77
• Bird fancier's disease in children Palmer J, Parker BR, Moss R, Lewiston NJ. Am J Asthma Allergy Pediatr. 1989: 3 45-52
• Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. Eichler I, Joris L, Hsu YP, Van Wye J, Bram R, Moss R. J Clin Invest. 1989; 84 (6): 1794-804
• Regarding article by Earl and Sullivan. Moss RB, J Allergy Clin Immunol. 1989; 83 (6): 1138
• Suppression of the late cutaneous response by immunotherapy. Fling JA, Ruff ME, Parker WA, Whisman BA, Martin ME, Moss RB, Reid MJ. J Allergy Clin Immunol. 1989; 83 (1): 101-9
• Mountain cedar pollinosis: can it occur in non-atopics? Reid MJ, Schwietz LA, Whisman BA, Moss RB. N Engl Reg Allergy Proc. 1988 May-Jun; 9 (3): 225-32
• The role of IgG subclass antibodies in chronic infection: the case of cystic fibrosis. Moss RB, N Engl Reg Allergy Proc. 1988 Jan-Feb; 9 (1): 57-61
• Allergy evaluation in children: skin testing and RAST Moss RB, Am J Asthma Allergy Pediatr. 1988: 110 101-8
• Assessment of validity of allergen reactivity with multiple skin prick testing, RAST, EAST, and rocket immunoelectrophoresi Eichler I, Gotz M, Jarisch R, Moss R. Allergy. 1988: 43 458-63
• Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis Smith AL, Redding G, Doershuk C, Goldman D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Rubio T, Schwartz R, Thomassen MJ, Williams-Warren J, Weber A, Wilmott R, Wilson D, Yogev R.. J Pediatr. 1988: 1112 547-54
• IgG subclass antibody markers in grass pollen immunotherapy. Moss RB, N Engl Reg Allergy Proc. 1987 Nov-Dec; 8 (6): 409-15
• Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens. Moss RB, Hsu YP, Van Eede PH, Van Leeuwen AM, Lewiston NJ, De Lange G. Pediatr Res. 1987; 22 (6): 708-13
• Antibody and immune complex production in cystic fibrosis Moss RB, Pediatr Pulmonol. 1987: Suppl 1 95-8
• Effect of total lymphoid irradiation on IgE antibody responses in rheumatoid arthritis and systemic lupus erythematosus. Terr AI, Moss RB, Strober S. J Allergy Clin Immunol. 1987; 80 (6): 798-802
• Hypergammaglobulinemia in cystic fibrosis. Role of Pseudomonas endobronchial infection. Moss RB, Chest. 1987; 91 (4): 522-6
• IgE antibodies in young children with possible allergic symptoms Lewiston NJ, Hindi R, Hsu YP, Lewiston J, Moss RB. J Pediatr. 1987: 110 738-40
• IgG subclass antibody markers in grass pollen immunotherapy Moss RB, Allergy Proceed. 1987: 8 409-15
• Interobserver variance in clinical scoring for cystic fibrosis Lewiston NJ, Moss RB, Hindi R, Rubinstein S, Sullivan MM. Chest. 1987: 91 878-92
• Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: correlation of rye group I antigen-specific IgG1 with clinical response. Moss RB, Hsu YP, Kwasnicki JM, Sullivan MM, Reid MJ. J Allergy Clin Immunol. 1987; 79 (2): 387-98
• Performance characteristics of immunoenzymatic testing for total and specific immunoglobulin E. Comparison of conventional assay with a microtiter plate accelerated computerized procedure Moss RB, Hsu Y, Esrig S. Ann Allergy. 1987: 59 185-91
• Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency. Moss RB, Hsu YP, Sullivan MM, Lewiston NJ. Pediatr Res. 1986; 20 (5): 453-9
• Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. Moss RB, Hsu YP, Lewiston NJ, Curd JG, Milgrom H, Hart S, Dyer B, Larrick JW. Am Rev Respir Dis. 1986; 133 (4): 648-52
• Constipation and meconium ileus equivalent in cystic fibrosis Rubinstein S, Moss RB, Lewiston NJ. Pediatrics. 1986: 78 473-9
• Cow's milk allergy in breast fed infants. Role of allergen and breast milk secretory IgA antibody Machtinger S, Moss RB. J Allergy Clin Immunol. 1986: 77 341-7
• Generation and characterization of human monoclonal anti-Pseudomonas aeruginosa antibodies Larrick JW, Hart SM, Lippman D, Glembourtt M, Hsu YP, Moss RB. Strelkauskas A (ed), Human Hybridomas: Diagnostic and Therapeutic Applications. Marcel Dekker, Inc., New York. 1986: 65-80
• IgG subclasses in respiratory disorders: cystic fibrosis Moss RB, Shakib F (ed), Basic and Clinical Aspects of IgG Subclasses. Monographs in Allergy, vol. 19. SW Karger, Basel. 1986: 202-9
• IgG subclasses in respiratory disorders: cystic fibrosis. Moss RB, Monogr Allergy. 1986: 19 202-9
• Immune complexes in CF: keys to new clinical insight Lewiston NJ, Moss RB.. J Respir Dis. 1986: 7 60-6
• Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL. J Allergy Clin Immunol. 1986; 78 (4 Pt 1): 590-600
• Supraventricular tachycardia in patients with cystic fibrosis. Sullivan MM, Moss RB, Hindi RD, Lewiston NJ. Chest. 1986; 90 (2): 239-42
• Cystic fibrosis and neuroblastoma. Moss RB, Blessing-Moore J, Bender SW, Weibel A. Pediatrics. 1985; 76 (5): 814-7
• In vitro expansion of human B cells for the production of human monoclonal antibodies Larrick JW, Dyer BJ, Senyk G, Hart SM, Moss RB, Lippman D, Jahnsen MC, Wang J, Weintraub H, Raubitschek AA. Engleman EG, Foung SKH, Larrick JW, Raubitschek AA (eds), Human Hybridomas and Monoclonal Antibodies. Plenum Press, NY. 1985: 149-65
• Underestimation of specific immunoglobulin E by microtiter plate enzyme-linked immunosorbent assays. Reid MJ, Kwasnicki JM, Moss RB, Cheung NK. J Allergy Clin Immunol. 1985; 76 (2 Pt 1): 172-6
• Allergic phenomena in cystic fibrosis Lewiston NJ, Moss RB. Shapira E, Wilson GB (eds), Immunological Aspects of Cystic Fibrosis. CRC Press Inc., Boca Raton. 1984: 125-47
• Allergy to semisynthetic penicillins in cystic fibrosis. Moss RB, Babin S, Hsu YP, Blessing-Moore J, Lewiston NJ. J Pediatr. 1984; 104 (3): 460-6
• Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. Ortolani C, Pastorello E, Moss RB, Hsu YP, Restuccia M, Joppolo G, Miadonna A, Cornelli U, Halpern G, Zanussi C. J Allergy Clin Immunol. 1984; 73 (2): 283-90
• Immunopathology of cystic fibrosis Moss RB, Shapira E, Wilson GB (eds), Immunological Aspects of Cystic Fibrosis. CRC Press Inc., Boca Raton. 1984: 5-27
• Sudden death in adolescent asthma. Rubinstein S, Hindi RD, Moss RB, Blessing-Moore J, Lewiston NJ. Ann Allergy. 1984; 53 (4): 311-8
• A microtiter immunoenzymatic assay for antigen-specific IgG4 subclass antibodies Hsu YP, Moss RB.. Clin Rev Allergy. 1983: 1 233-6
• Enzyme immunoassay for honeybee venom specific IgG4 Halpern GM, Moss RB, Hsu YP, Blessing J. Avrameas S (ed), Immunoenzymatic Techniques. Elsevier Science Publishers, Amsterdam. 1983: 395-401
• IgG4 antibody to Pseudomonas aeruginosa in cystic fibrosis Moss RB, Hsu YP, Leahy M, Halpern G. Kerr JW, Ganderton MA (eds), Proceedings of Invited Symposia, XII International Congress of Allergology and Clinical Immunology, Macmillan, London. 1983: 351-5
• Immunology of cystic fibrosis: immunity, immunodeficiency, and hypersensitivity. Moss RB, Lloyd-Still JD (ed), Textbook of Cystic Fibrosis. Wright-PSG Publishing Inc., Boston. 1983: 109-51
• Microtiter immunoenzymatic assay (micro-ELISA) for antigen-specific IgG4 subclass antibody. Hsu YP, Moss RB. Clin Rev Allergy. 1983; 1 (2): 231-6
• Isolation and characterization of circulating immune complexes in cystic fibrosis. Moss RB, Hsu YP. Clin Exp Immunol. 1982; 47 (2): 301-8
• 125I-Clq-binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis. Moss RB, Hsu YP, Lewiston NJ. J Pediatr. 1981; 99 (2): 215-22
• Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. Moss RB, Lewiston NJ. Am Rev Respir Dis. 1980; 121 (1): 23-9
• Chronic neuropathy presenting as a floppy infant with respiratory distress. Moss RB, Sriram S, Kelts KA, Forno LS, Lewiston NJ. Pediatrics. 1979; 64 (4): 459-64
• Cuirass ventilation in childhood neuromuscular disease O'Leary J, Moss RB, King R, Liebhaber M, Lewiston N. J Pediatr. 1979: 94 419-21
• The immunologic and clinical associations of the split products of C'3 in plasma in juvenile rheumatoid arthritis Miller JJ, Hsu YP, Moss RB, Olds L. Arth Rheum. 1979: 22 502-7